The clinical trial shall include 40 children, and is designed as a method-comparison study, where bilirubin analyzed with Calmark Neo is compared with the hospital laboratory’s analytical results. The latter is used as the reference method in the comparison.
The inclusion criterion is for the infant to have a suspected elevated level of bilirubin (risk of jaundice), requiring a blood test to be taken. The launch of the study coincided with the Christmas and New Year holiday period, and all units did not receive the information. As from this week, all units at Södersjukhuset are involved in the trial, and the infant inclusion rate is rising.
"We are satisfied that the trial now has gotten off the ground, and that the recruitment of patients is proceeding as intended", says Anna Söderlund, CEO of Calmark. "The market launch effort comprises many parts that are commencing in parallel; hence, it is our assessment that this minor delay will not impact the launch of sales."
This information is information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on 28 January 2020, 18:40 CET.
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.